Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–67.

Article  PubMed  Google Scholar 

Mohty M, Holler E, Jagasia M, Jenq R, Malard F, Martin P, Socie G, Zeiser R. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020;136(17):1903–6.

Article  PubMed  Google Scholar 

Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377(22):2167–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeiser R. Introduction to a review series on pathophysiology and treatment of acute GVHD. Blood. 2020;136(4):375–6.

Article  CAS  PubMed  Google Scholar 

Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood. 2020;136(4):429–40.

Article  PubMed  PubMed Central  Google Scholar 

Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(5):1229–40.

Article  PubMed  PubMed Central  Google Scholar 

Zeiser R, Socie G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJ, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022;9(1):e14–25.

Article  CAS  PubMed  Google Scholar 

Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, Ho VT, Cutler C, Alyea EP, Antin JH, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104(5):1559–64.

Article  CAS  PubMed  Google Scholar 

Bolanos-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22):3221–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, Ramsay M, McGlave P, Filipovich A, Weisdorf D. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6(4A):441–7.

Article  CAS  PubMed  Google Scholar 

Rashidi A, DiPersio JF, Sandmaier BM, Colditz GA, Weisdorf DJ. Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Biol Blood Marrow Transplant. 2016;22(6):1133–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Xu LP, Liu KY, Liu DH, Wang J, Chen H, Chen YH, Han W, Huang XJ. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility. Bone Marrow Transplant. 2011;46(6):892–8.

Article  CAS  PubMed  Google Scholar 

Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42(2):139–51.

Article  CAS  PubMed  Google Scholar 

Shiratori S, Ohigashi H, Takahashi S, Ara T, Goto H, Nakagawa M, Sugita J, Onozawa M, Kahata K, Endo T, et al. Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation. Ann Hematol. 2020;99(3):591–8.

Article  CAS  PubMed  Google Scholar 

de Lavallade H, Mohty M, Faucher C, Furst S, El-Cheikh J, Blaise D. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica. 2006;91(10):1438–40.

PubMed  Google Scholar 

Xu ZL, Mo XD, Kong Y, et al. Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: a phase 2 trial. J Transl Int Med. 2023;11(3):255–64. https://doi.org/10.2478/jtim-2022-0071.

Article  PubMed  PubMed Central  Google Scholar 

Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, et al. Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol. 2016;34(16):1855–63.

Article  CAS  PubMed  Google Scholar 

Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, Lai YR, Liu DH, Liu QF, Liu T, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843–50.

Article  CAS  PubMed  Google Scholar 

Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, Huang XJ. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull (Beijing). 2021;66(24):2498–505.

Article  CAS  PubMed  Google Scholar 

Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, Flowers ME, Storb R, Boeckh M, Martin PJ. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 2015;100(6):842–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, Nash RA, Flowers ME, Doney K, Lee S, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–15.

Article  PubMed  PubMed Central  Google Scholar 

Liu SN, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. Am J Hematol. 2020;95(8):927–36.

Article  CAS  PubMed  Google Scholar 

Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, Sun ZM, Zhang WJ, Liu QF, Liu DH, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am J Hematol. 2022;97(4):458–69.

Article  CAS  PubMed  Google Scholar 

MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JL, Jones R, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761–7.

Article  PubMed  PubMed Central  Google Scholar 

Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant. 2009;15(7):777–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu WB, Sun YQ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YY, Han W, Wang FR, et al. Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2020;41(2):106–11.

CAS  PubMed  Google Scholar 

Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, et al. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011;2011:601953.

Article  PubMed  PubMed Central  Google Scholar 

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, et al. Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica. 2017;102(12):2125–33.

Article  CAS  PubMed  PubMed Central